Checkpoint Therapeutics, Inc - CKPT Company Cash Funds

Brandmark of Checkpoint Therapeutics Inc (CKPT)

High binary risk stemming from a narrow focus on a single antibody creates uncertainty for capital. The level of cash reserves demonstrates the business's adaptability, where 0.03 represents the latest metric reading. However, diversification across various tumor types mitigates clinical threats. The potential launch of accessible cosibelimab in the US and FDA approval will serve as key growth catalysts for Checkpoint Therapeutics (CKPT).

CKPT - Checkpoint Therapeutics, Inc Company Liquid Assets over the range 07/04/2022 - 06/07/2025

Comprehensive metric breakdowns and analytics for Checkpoint Therapeutics, Inc (CKPT)

Fundamental valuation:Checkpoint Therapeutics, Inc CKPT
Product sample of Checkpoint Therapeutics Inc.

Liquidity monitoring that eliminates cash flow gaps is critical for long-term risk management for Checkpoint Therapeutics (CKPT). The specifics of developing cancer immunotherapy require colossal expenditures prior to the commercialization of cosibelimab. By analyzing cash levels, an investor sees the actual remaining funds in real-time rather than once a quarter. This metric measures the company's ability to fund clinical trials without emergency secondary offerings. A stable cash reserve confirms the financial stability of the business.

Key competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|SELLAS Life Sciences Group - Company Cash Volume|ACTU - Company Cash Volume|CTOR: Company Cash Volume|Company Cash Reserve TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Company Cash Volume|Fate Therapeutics, Inc. (FATE) - Company Liquid Assets|Company Cash on Hand WHWK (Aadi Bioscience, Inc.)|Company Liquid Assets TScan Therapeutics, Inc.|Company Cash Volume CSBR (Champions Oncology Corp)|Company Total Cash Amount XBIT (XBiotech USA)|CVM - Company Cash Funds|Company Cash Balance OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Company Cash Funds|ARTV: Company Total Cash Amount|ANL (adlainortye.com) - Company Cash Volume|VERU: Company Cash Balance|Company Cash on Hand TPST (Tempest Tx)|Company Cash on Hand Xilio XLO|Company Cash Volume RENB (Renovaro)|Company Cash Volume Mural Bio MURA|Kairos Pharma Ltd - Company Cash Volume|OnKure Therapeutics (OKUR) - Company Cash on Hand|GDTC: Company Cash Volume|Curis Inc. - Company Cash Balance|Company Cash Funds apollomicsinc.com|THAR: Company Cash Balance|Company Cash Funds Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Company Cash Balance|Company Cash Volume CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Company Cash Reserve|Xenetic Bio - Company Cash Volume|SLRX (Salarius Pharmaceuticals, Inc.) - Company Cash and Cash Equivalents|PPBT: Company Cash Volume|Company Cash on Hand American Oncology Network Inc|BGNE (beigene.com) - Company Cash Volume|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds